Long-term changes in crystalline lens transparency after accelerated transepithelial corneal cross-linking in patients with keratoconus

Eur J Ophthalmol. 2023 Sep;33(5):1850-1859. doi: 10.1177/11206721231170036. Epub 2023 Apr 19.

Abstract

Purpose: To investigate the long-term clinical outcomes and changes in crystalline lens transparency after accelerated (45 mW/cm2) transepithelial corneal cross-linking (ATE-CXL) using the Pentacam imaging system in patients with progressive keratoconus.

Methods: The study prospectively included 44 keratoconus eyes of 40 patients (mean age: 24.39 ± 5.61 years) who underwent ATE-CXL. The examinations, including assessment of uncorrected distance visual acuity, corrected distance visual acuity, corneal topography, and corneal endothelial cell density count, were conducted preoperatively and 1 month, 3 months, 6 months, 1 year, and 5 years postoperatively. Measurement of crystalline lens density using Pentacam images was also performed pre- and postoperatively.

Results: All surgeries were uneventful with no postoperative complications. All keratometry values and corneal thickness remained stable during the 5-year follow-up period (all p > 0.05). There were no significant differences in corneal endothelial cell density count, visual acuity, and anterior average lens density in the 0.5-, 1.0-, and 1.5-mm depth zones during the 5-year follow-up period compared with the preoperative values (all p > 0.05).

Conclusion: The results of this study suggest that ATE-CXL at 45 mW/cm2 is safe and effective for the treatment of progressive keratoconus in terms of both crystalline lens density and endothelial cell density.

Keywords: cross-linking; keratoconus; lens density; transepithelial.

MeSH terms

  • Adolescent
  • Adult
  • Collagen / therapeutic use
  • Corneal Cross-Linking
  • Corneal Topography
  • Cross-Linking Reagents / therapeutic use
  • Humans
  • Keratoconus* / diagnosis
  • Keratoconus* / drug therapy
  • Lens, Crystalline*
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Riboflavin / therapeutic use
  • Ultraviolet Rays
  • Young Adult

Substances

  • Photosensitizing Agents
  • Riboflavin
  • Collagen
  • Cross-Linking Reagents